SalfaCorp Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

SalfaCorp heeft een totaal eigen vermogen van CLP507.3B en een totale schuld van CLP497.8B, wat de schuld-eigenvermogensverhouding op 98.1% brengt. De totale activa en totale passiva bedragen respectievelijk CLP1,489.4B en CLP982.1B. De EBIT SalfaCorp is CLP73.0B waardoor de rentedekking 4.6 is. Het heeft contanten en kortetermijnbeleggingen van CLP76.8B.

Belangrijke informatie

98.1%

Verhouding schuld/eigen vermogen

CL$497.84b

Schuld

Rente dekkingsratio	4.6x
Contant	CL$76.77b
Aandelen	CL$507.25b
Totaal verplichtingen	CL$982.14b
Totaal activa	CL$1.49t

Recente financiële gezondheidsupdates

Recent updates

SalfaCorp (SNSE:SALFACORP) Takes On Some Risk With Its Use Of Debt

Nov 08

At CL$297, Is It Time To Put SalfaCorp S.A. (SNSE:SALFACORP) On Your Watch List?

Jan 27

SalfaCorp (SNSE:SALFACORP) Shareholders Will Want The ROCE Trajectory To Continue

Nov 03

At CL$361, Is SalfaCorp S.A. (SNSE:SALFACORP) Worth Looking At Closely?

Sep 07

SalfaCorp (SNSE:SALFACORP) Has More To Do To Multiply In Value Going Forward

May 28

Is SalfaCorp (SNSE:SALFACORP) A Risky Investment?

Feb 08

SalfaCorp (SNSE:SALFACORP) Might Be Having Difficulty Using Its Capital Effectively

Nov 23

At CL$310, Is It Time To Put SalfaCorp S.A. (SNSE:SALFACORP) On Your Watch List?

Nov 05

SalfaCorp (SNSE:SALFACORP) Takes On Some Risk With Its Use Of Debt

Oct 18

We Think You Can Look Beyond SalfaCorp's (SNSE:SALFACORP) Lackluster Earnings

Jun 04

SalfaCorp (SNSE:SALFACORP) Seems To Be Using A Lot Of Debt

Mar 24

A Look At The Intrinsic Value Of SalfaCorp S.A. (SNSE:SALFACORP)

Feb 24

Has SalfaCorp (SNSE:SALFACORP) Got What It Takes To Become A Multi-Bagger?

Feb 04

Is SalfaCorp S.A. (SNSE:SALFACORP) An Attractive Dividend Stock?

Jan 16

Reflecting on SalfaCorp's (SNSE:SALFACORP) Share Price Returns Over The Last Three Years

Jan 01

Is SalfaCorp S.A. (SNSE:SALFACORP) Popular Amongst Institutions?

Dec 12

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CLP570.0B ) van SALFACORP } dekken niet de korte termijn passiva ( CLP652.9B ).

Langlopende schulden: De kortetermijnactiva SALFACORP ( CLP570.0B ) overtreffen de langetermijnschulden ( CLP329.3B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 83% ) SALFACORP wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van SALFACORP is de afgelopen 5 jaar gedaald van 113.4% naar 98.1%.

Schuldendekking: De schuld van SALFACORP wordt niet goed gedekt door de operationele kasstroom ( 11.3% ).

Rentedekking: De rentebetalingen op de schuld van SALFACORP worden goed gedekt door EBIT ( 4.6 x dekking).

SalfaCorp Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

SalfaCorp (SNSE:SALFACORP) Takes On Some Risk With Its Use Of Debt

Is SalfaCorp (SNSE:SALFACORP) A Risky Investment?

SalfaCorp (SNSE:SALFACORP) Takes On Some Risk With Its Use Of Debt

SalfaCorp (SNSE:SALFACORP) Seems To Be Using A Lot Of Debt

Recent updates

New major risk - Financial position

Third quarter 2024 earnings released: EPS: CL$16.87 (vs CL$21.01 in 3Q 2023)

Second quarter 2024 earnings released: EPS: CL$23.10 (vs CL$21.00 in 2Q 2023)

New major risk - Financial position

First quarter 2024 earnings released: EPS: CL$21.13 (vs CL$18.27 in 1Q 2023)

Insufficient new directors

Upcoming dividend of CL$23.40 per share

New major risk - Financial position

Full year 2023 earnings released: EPS: CL$77.96 (vs CL$79.21 in FY 2022)

New minor risk - Financial position

Price target increased by 18% to CL$490

Third quarter 2023 earnings released: EPS: CL$21.01 (vs CL$24.38 in 3Q 2022)

Investor sentiment improves as stock rises 17%

SalfaCorp (SNSE:SALFACORP) Takes On Some Risk With Its Use Of Debt

Second quarter 2023 earnings released: EPS: CL$21.00 (vs CL$20.85 in 2Q 2022)

Price target increased by 15% to CL$415

New minor risk - Shareholder dilution

New minor risk - Share price stability

Upcoming dividend of CL$19.45 per share at 5.9% yield

Full year 2022 earnings released: EPS: CL$79.21 (vs CL$68.49 in FY 2021)

At CL$297, Is It Time To Put SalfaCorp S.A. (SNSE:SALFACORP) On Your Watch List?

Price target decreased to CL$360

Investor sentiment deteriorated over the past week

SalfaCorp (SNSE:SALFACORP) Shareholders Will Want The ROCE Trajectory To Continue

At CL$361, Is SalfaCorp S.A. (SNSE:SALFACORP) Worth Looking At Closely?

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CL$20.84 (vs CL$15.89 in 2Q 2021)

SalfaCorp (SNSE:SALFACORP) Has More To Do To Multiply In Value Going Forward

Upcoming dividend of CL$20.55 per share

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Is SalfaCorp (SNSE:SALFACORP) A Risky Investment?

Investor sentiment improved over the past week

SalfaCorp (SNSE:SALFACORP) Might Be Having Difficulty Using Its Capital Effectively

Third quarter 2021 earnings released: EPS CL$16.18 (vs CL$5.77 in 3Q 2020)

Investor sentiment improved over the past week

At CL$310, Is It Time To Put SalfaCorp S.A. (SNSE:SALFACORP) On Your Watch List?

SalfaCorp (SNSE:SALFACORP) Takes On Some Risk With Its Use Of Debt

Second quarter 2021 earnings released: EPS CL$15.89 (vs CL$5.38 in 2Q 2020)

We Think You Can Look Beyond SalfaCorp's (SNSE:SALFACORP) Lackluster Earnings

Investor sentiment deteriorated over the past week

Upcoming dividend of CL$9.17 per share

SalfaCorp (SNSE:SALFACORP) Seems To Be Using A Lot Of Debt

New 90-day high: CL$545

A Look At The Intrinsic Value Of SalfaCorp S.A. (SNSE:SALFACORP)

Full year 2020 earnings released: EPS CL$30.56 (vs CL$51.66 in FY 2019)

Has SalfaCorp (SNSE:SALFACORP) Got What It Takes To Become A Multi-Bagger?

Is SalfaCorp S.A. (SNSE:SALFACORP) An Attractive Dividend Stock?

New 90-day high: CL$432

Reflecting on SalfaCorp's (SNSE:SALFACORP) Share Price Returns Over The Last Three Years

Is SalfaCorp S.A. (SNSE:SALFACORP) Popular Amongst Institutions?

Third quarter 2020 earnings released: EPS CL$5.77

New 90-day low: CL$396

New 90-day low: CL$400

First half earnings released

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven